255 related articles for article (PubMed ID: 20163515)
1. Potential of nonpeptide (ant)agonists to rescue vasopressin V2 receptor mutants for the treatment of X-linked nephrogenic diabetes insipidus.
Los EL; Deen PM; Robben JH
J Neuroendocrinol; 2010 May; 22(5):393-9. PubMed ID: 20163515
[TBL] [Abstract][Full Text] [Related]
2. Functional rescue of vasopressin V2 receptor mutants in MDCK cells by pharmacochaperones: relevance to therapy of nephrogenic diabetes insipidus.
Robben JH; Sze M; Knoers NV; Deen PM
Am J Physiol Renal Physiol; 2007 Jan; 292(1):F253-60. PubMed ID: 16926443
[TBL] [Abstract][Full Text] [Related]
3. Characterization of vasopressin V2 receptor mutants in nephrogenic diabetes insipidus in a polarized cell model.
Robben JH; Knoers NV; Deen PM
Am J Physiol Renal Physiol; 2005 Aug; 289(2):F265-72. PubMed ID: 16006591
[TBL] [Abstract][Full Text] [Related]
4. V2R mutations and nephrogenic diabetes insipidus.
Bichet DG
Prog Mol Biol Transl Sci; 2009; 89():15-29. PubMed ID: 20374732
[TBL] [Abstract][Full Text] [Related]
5. Cell biological aspects of the vasopressin type-2 receptor and aquaporin 2 water channel in nephrogenic diabetes insipidus.
Robben JH; Knoers NV; Deen PM
Am J Physiol Renal Physiol; 2006 Aug; 291(2):F257-70. PubMed ID: 16825342
[TBL] [Abstract][Full Text] [Related]
6. Molecular genetic study of congenital nephrogenic diabetes insipidus and rescue of mutant vasopressin V2 receptor by chemical chaperones.
Cheong HI; Cho HY; Park HW; Ha IS; Choi Y
Nephrology (Carlton); 2007 Apr; 12(2):113-7. PubMed ID: 17371330
[TBL] [Abstract][Full Text] [Related]
7. Intracellular activation of vasopressin V2 receptor mutants in nephrogenic diabetes insipidus by nonpeptide agonists.
Robben JH; Kortenoeven ML; Sze M; Yae C; Milligan G; Oorschot VM; Klumperman J; Knoers NV; Deen PM
Proc Natl Acad Sci U S A; 2009 Jul; 106(29):12195-200. PubMed ID: 19587238
[TBL] [Abstract][Full Text] [Related]
8. Effect of the cGMP pathway on AQP2 expression and translocation: potential implications for nephrogenic diabetes insipidus.
Boone M; Kortenoeven M; Robben JH; Deen PM
Nephrol Dial Transplant; 2010 Jan; 25(1):48-54. PubMed ID: 19666909
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological chaperones in nephrogenic diabetes insipidus: possibilities for clinical application.
Robben JH; Deen PM
BioDrugs; 2007; 21(3):157-66. PubMed ID: 17516711
[TBL] [Abstract][Full Text] [Related]
10. Nephrogenic diabetes insipidus.
Bichet DG
Adv Chronic Kidney Dis; 2006 Apr; 13(2):96-104. PubMed ID: 16580609
[TBL] [Abstract][Full Text] [Related]
11. Pharmacologic chaperones as a potential treatment for X-linked nephrogenic diabetes insipidus.
Bernier V; Morello JP; Zarruk A; Debrand N; Salahpour A; Lonergan M; Arthus MF; Laperrière A; Brouard R; Bouvier M; Bichet DG
J Am Soc Nephrol; 2006 Jan; 17(1):232-43. PubMed ID: 16319185
[TBL] [Abstract][Full Text] [Related]
12. Vasopressin receptors and pharmacological chaperones: from functional rescue to promising therapeutic strategies.
Mouillac B; Mendre C
Pharmacol Res; 2014 May; 83():74-8. PubMed ID: 24239889
[TBL] [Abstract][Full Text] [Related]
13. Diverse vasopressin V2 receptor functionality underlying partial congenital nephrogenic diabetes insipidus.
Faerch M; Christensen JH; Rittig S; Johansson JO; Gregersen N; de Zegher F; Corydon TJ
Am J Physiol Renal Physiol; 2009 Dec; 297(6):F1518-25. PubMed ID: 19812297
[TBL] [Abstract][Full Text] [Related]
14. [From genes to disease: from vasopressin-V2-receptor and aquaporine-2 to nephrogenic diabetes insipidus].
Knoers NV; Deen PM
Ned Tijdschr Geneeskd; 2000 Dec; 144(50):2402-4. PubMed ID: 11145096
[TBL] [Abstract][Full Text] [Related]
15. Vasopressin receptor mutations in nephrogenic diabetes insipidus.
Bichet DG
Semin Nephrol; 2008 May; 28(3):245-51. PubMed ID: 18519085
[TBL] [Abstract][Full Text] [Related]
16. Analysis of the V2 Vasopressin Receptor (V2R) Mutations Causing Partial Nephrogenic Diabetes Insipidus Highlights a Sustainable Signaling by a Non-peptide V2R Agonist.
Makita N; Sato T; Yajima-Shoji Y; Sato J; Manaka K; Eda-Hashimoto M; Ootaki M; Matsumoto N; Nangaku M; Iiri T
J Biol Chem; 2016 Oct; 291(43):22460-22471. PubMed ID: 27601473
[TBL] [Abstract][Full Text] [Related]
17. Identification, characterization and rescue of a novel vasopressin-2 receptor mutation causing nephrogenic diabetes insipidus.
Ranadive SA; Ersoy B; Favre H; Cheung CC; Rosenthal SM; Miller WL; Vaisse C
Clin Endocrinol (Oxf); 2009 Sep; 71(3):388-93. PubMed ID: 19170711
[TBL] [Abstract][Full Text] [Related]
18. Aquaporin 2 mutations in nephrogenic diabetes insipidus.
Loonen AJ; Knoers NV; van Os CH; Deen PM
Semin Nephrol; 2008 May; 28(3):252-65. PubMed ID: 18519086
[TBL] [Abstract][Full Text] [Related]
19. [Nephrogenic diabetes insipidus associated with mutations of vasopressin V2 receptors and aquaporin-2].
Ishikawa SE
Nihon Rinsho; 2002 Feb; 60(2):350-5. PubMed ID: 11857925
[TBL] [Abstract][Full Text] [Related]
20. Molecular and cellular defects in nephrogenic diabetes insipidus.
Knoers NV; Deen PM
Pediatr Nephrol; 2001 Dec; 16(12):1146-52. PubMed ID: 11793119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
